# To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

> **NCT06376474** · PHASE1 · RECRUITING · sponsor: **Ganzhou Hemay Pharmaceutical Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Hemay005

## Key facts

- **NCT ID:** NCT06376474
- **Lead sponsor:** Ganzhou Hemay Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-28
- **Primary completion:** 2025-12-10
- **Final completion:** 2025-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06376474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06376474, "To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06376474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*